Last 12 months
Inside the activity.
0 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 17, 2026 20:17 UTC |
KIIL HARRY SKIPEVP & President Cardiovascular
|
SaleOrdinary Shares | 1,483 | $93.65 | $138,882.95 |
DisclosureSEC source: 0001708062-26-000012 · wk-form4_1789676262.xml · nonDerivative · entry 1 KIIL HARRY SKIP · CIK 0001708062 · EVP & President Cardiovascular 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,186 Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:16 UTC |
Blomquist Denise L.Chief Accounting Officer
|
GiftOrdinary Shares | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0002061393-26-000014 · wk-form4_1789589777.xml · nonDerivative · entry 1 Blomquist Denise L. · CIK 0002061393 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,398 Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 21:04 UTC |
Marinaro MichaelEVP, Pres MedSurg and Americas
|
Tax withholdingOrdinary Shares | 1,084 | $92.30 | $100,053.20 |
DisclosureSEC source: 0001984186-26-000008 · wk-form4_1787605444.xml · nonDerivative · entry 1 Marinaro Michael · CIK 0001984186 · EVP, Pres MedSurg and Americas 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,336 F1 · shares: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:59 UTC |
Pieton ThierryEVP & Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 81,945 | $0.00 Strike: $86.68 | $0.00 |
DisclosureSEC source: 0002056622-26-000003 · wk-form4_1785887944.xml · derivative · entry 3 Pieton Thierry · CIK 0002056622 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,945 Underlying: Ordinary Shares · 81,945 shares Expires 2036-08-03 F6 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:59 UTC |
Pieton ThierryEVP & Chief Financial Officer
|
GrantPerformance Share Units · Derivative | 28,842 | $0.00 | $0.00 |
DisclosureSEC source: 0002056622-26-000003 · wk-form4_1785887944.xml · derivative · entry 2 Pieton Thierry · CIK 0002056622 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,842 Underlying: Ordinary Shares · 28,842 shares Expires not disclosed F3 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F4 · derivative.exercise_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F4 · derivative.expiration_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F5 · derivative.underlying_shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 28,842 shares will be issued. If maximum performance metrics are achieved, 69,221 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:59 UTC |
Pieton ThierryEVP & Chief Financial Officer
|
GrantOrdinary Shares | 11,537 | $0.00 | $0.00 |
DisclosureSEC source: 0002056622-26-000003 · wk-form4_1785887944.xml · nonDerivative · entry 1 Pieton Thierry · CIK 0002056622 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,645 F1 · shares: Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F2 · balance_after: Includes 534 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 00:00 UTC |
Walter Matthew R.SVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 40,973 | $0.00 Strike: $86.68 | $0.00 |
DisclosureSEC source: 0002028475-26-000010 · wk-form4_1785888007.xml · derivative · entry 4 Walter Matthew R. · CIK 0002028475 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,973 Underlying: Ordinary Shares · 40,973 shares Expires 2036-08-03 F7 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 00:00 UTC |
Walter Matthew R.SVP, Chief HR Officer
|
GrantPerformance Share Units · Derivative | 14,421 | $0.00 | $0.00 |
DisclosureSEC source: 0002028475-26-000010 · wk-form4_1785888007.xml · derivative · entry 3 Walter Matthew R. · CIK 0002028475 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,421 Underlying: Ordinary Shares · 14,421 shares Expires not disclosed F4 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 · derivative.exercise_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F5 · derivative.expiration_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 · derivative.underlying_shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 14,421 shares will be issued. If maximum performance metrics are achieved, 34,610 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 00:00 UTC |
Walter Matthew R.SVP, Chief HR Officer
|
GrantOrdinary Shares | 5,769 | $0.00 | $0.00 |
DisclosureSEC source: 0002028475-26-000010 · wk-form4_1785888007.xml · nonDerivative · entry 2 Walter Matthew R. · CIK 0002028475 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,928 F3 · shares: Represents restricted stock units that vest 100% on the third anniversary of the date of grant. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:57 UTC |
Martha GeoffreyDirector · Chairman and CEO
|
GrantStock Option (Right to Buy) · Derivative | 273,150 | $0.00 Strike: $86.68 | $0.00 |
DisclosureSEC source: 0001560409-26-000008 · wk-form4_1785887872.xml · derivative · entry 5 Martha Geoffrey · CIK 0001560409 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,150 Underlying: Ordinary Shares · 273,150 shares Expires 2036-08-03 F7 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:57 UTC |
Martha GeoffreyDirector · Chairman and CEO
|
GrantStock Option (Right to Buy) · Derivative | 295,002 | $0.00 Strike: $86.68 | $0.00 |
DisclosureSEC source: 0001560409-26-000008 · wk-form4_1785887872.xml · derivative · entry 4 Martha Geoffrey · CIK 0001560409 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,002 Underlying: Ordinary Shares · 295,002 shares Expires 2036-08-03 F7 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:57 UTC |
Martha GeoffreyDirector · Chairman and CEO
|
GrantPerformance Share Units · Derivative | 103,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001560409-26-000008 · wk-form4_1785887872.xml · derivative · entry 3 Martha Geoffrey · CIK 0001560409 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,831 Underlying: Ordinary Shares · 103,831 shares Expires not disclosed F4 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 · derivative.exercise_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F5 · derivative.expiration_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 · derivative.underlying_shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 103,831 shares will be issued. If maximum performance metrics are achieved, 249,194 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:57 UTC |
Martha GeoffreyDirector · Chairman and CEO
|
GrantOrdinary Shares | 41,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001560409-26-000008 · wk-form4_1785887872.xml · nonDerivative · entry 2 Martha Geoffrey · CIK 0001560409 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,866 F3 · shares: Represents restricted stock units that vest 100% on the third anniversary of the date of grant. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 00:00 UTC |
Blomquist Denise L.Chief Accounting Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,366 | $0.00 Strike: $86.68 | $0.00 |
DisclosureSEC source: 0002061393-26-000012 · wk-form4_1785888034.xml · derivative · entry 4 Blomquist Denise L. · CIK 0002061393 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,366 Underlying: Ordinary Shares · 1,366 shares Expires 2036-08-03 F7 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 00:00 UTC |
Blomquist Denise L.Chief Accounting Officer
|
GrantPerformance Share Units · Derivative | 2,337 | $0.00 | $0.00 |
DisclosureSEC source: 0002061393-26-000012 · wk-form4_1785888034.xml · derivative · entry 3 Blomquist Denise L. · CIK 0002061393 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,337 Underlying: Ordinary Shares · 2,337 shares Expires not disclosed F4 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 · derivative.exercise_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F5 · derivative.expiration_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 · derivative.underlying_shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 2,337 shares will be issued. If maximum performance metrics are achieved, 5,609 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 00:00 UTC |
Blomquist Denise L.Chief Accounting Officer
|
GrantOrdinary Shares | 2,337 | $0.00 | $0.00 |
DisclosureSEC source: 0002061393-26-000012 · wk-form4_1785888034.xml · nonDerivative · entry 2 Blomquist Denise L. · CIK 0002061393 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,998 F3 · shares: Represents restricted stock units that vest 100% on the third anniversary of the date of grant. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:59 UTC |
Thompson KweliEVP & President, Neuroscience
|
GrantStock Option (Right to Buy) · Derivative | 49,167 | $0.00 Strike: $86.68 | $0.00 |
DisclosureSEC source: 0002137804-26-000004 · wk-form4_1785887983.xml · derivative · entry 4 Thompson Kweli · CIK 0002137804 · EVP & President, Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,167 Underlying: Ordinary Shares · 49,167 shares Expires 2036-08-03 F7 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:59 UTC |
Thompson KweliEVP & President, Neuroscience
|
GrantPerformance Share Units · Derivative | 17,306 | $0.00 | $0.00 |
DisclosureSEC source: 0002137804-26-000004 · wk-form4_1785887983.xml · derivative · entry 3 Thompson Kweli · CIK 0002137804 · EVP & President, Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,306 Underlying: Ordinary Shares · 17,306 shares Expires not disclosed F4 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 · derivative.exercise_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F5 · derivative.expiration_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 · derivative.underlying_shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 17,306 shares will be issued. If maximum performance metrics are achieved, 41,534 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:59 UTC |
Thompson KweliEVP & President, Neuroscience
|
GrantOrdinary Shares | 6,923 | $0.00 | $0.00 |
DisclosureSEC source: 0002137804-26-000004 · wk-form4_1785887983.xml · nonDerivative · entry 2 Thompson Kweli · CIK 0002137804 · EVP & President, Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,390 F3 · shares: Represents restricted stock units that vest 100% on the third anniversary of the date of grant. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:59 UTC |
Quinn MichelleEVP, GC and Secretary
|
GrantStock Option (Right to Buy) · Derivative | 45,070 | $0.00 Strike: $86.68 | $0.00 |
DisclosureSEC source: 0001964281-26-000004 · wk-form4_1785887963.xml · derivative · entry 3 Quinn Michelle · CIK 0001964281 · EVP, GC and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,070 Underlying: Ordinary Shares · 45,070 shares Expires 2036-08-03 F5 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:59 UTC |
Quinn MichelleEVP, GC and Secretary
|
GrantPerformance Share Units · Derivative | 15,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001964281-26-000004 · wk-form4_1785887963.xml · derivative · entry 2 Quinn Michelle · CIK 0001964281 · EVP, GC and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,863 Underlying: Ordinary Shares · 15,863 shares Expires not disclosed F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F3 · derivative.exercise_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F3 · derivative.expiration_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F4 · derivative.underlying_shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 15,863 shares will be issued. If maximum performance metrics are achieved, 38,071 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:59 UTC |
Quinn MichelleEVP, GC and Secretary
|
GrantOrdinary Shares | 6,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001964281-26-000004 · wk-form4_1785887963.xml · nonDerivative · entry 1 Quinn Michelle · CIK 0001964281 · EVP, GC and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,721 F1 · shares: Represents restricted stock units that vest 100% on the third anniversary of the date of grant. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:58 UTC |
Marinaro MichaelEVP, Pres MedSurg and Americas
|
GrantStock Option (Right to Buy) · Derivative | 77,848 | $0.00 Strike: $86.68 | $0.00 |
DisclosureSEC source: 0001984186-26-000006 · wk-form4_1785887926.xml · derivative · entry 5 Marinaro Michael · CIK 0001984186 · EVP, Pres MedSurg and Americas 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,848 Underlying: Ordinary Shares · 77,848 shares Expires 2036-08-03 F8 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:58 UTC |
Marinaro MichaelEVP, Pres MedSurg and Americas
|
GrantPerformance Share Units · Derivative | 27,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001984186-26-000006 · wk-form4_1785887926.xml · derivative · entry 4 Marinaro Michael · CIK 0001984186 · EVP, Pres MedSurg and Americas 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,400 Underlying: Ordinary Shares · 27,400 shares Expires not disclosed F5 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F6 · derivative.exercise_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 · derivative.expiration_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F7 · derivative.underlying_shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 27,400 shares will be issued. If maximum performance metrics are achieved, 65,760 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:58 UTC |
Marinaro MichaelEVP, Pres MedSurg and Americas
|
GrantOrdinary Shares | 46,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001984186-26-000006 · wk-form4_1785887926.xml · nonDerivative · entry 3 Marinaro Michael · CIK 0001984186 · EVP, Pres MedSurg and Americas 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,420 F4 · shares: Represents restricted stock units that vest in four annual installments beginning one year from the date of grant. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:58 UTC |
Marinaro MichaelEVP, Pres MedSurg and Americas
|
GrantOrdinary Shares | 10,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001984186-26-000006 · wk-form4_1785887926.xml · nonDerivative · entry 2 Marinaro Michael · CIK 0001984186 · EVP, Pres MedSurg and Americas 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,273 F3 · shares: Represents restricted stock units that vest 100% on the third anniversary of the date of grant. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:58 UTC |
KIIL HARRY SKIPEVP & President Cardiovascular
|
GrantStock Option (Right to Buy) · Derivative | 65,556 | $0.00 Strike: $86.68 | $0.00 |
DisclosureSEC source: 0001708062-26-000010 · wk-form4_1785887900.xml · derivative · entry 4 KIIL HARRY SKIP · CIK 0001708062 · EVP & President Cardiovascular 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,556 Underlying: Ordinary Shares · 65,556 shares Expires 2036-08-03 F7 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:58 UTC |
KIIL HARRY SKIPEVP & President Cardiovascular
|
GrantPerformance Share Units · Derivative | 23,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001708062-26-000010 · wk-form4_1785887900.xml · derivative · entry 3 KIIL HARRY SKIP · CIK 0001708062 · EVP & President Cardiovascular 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,074 Underlying: Ordinary Shares · 23,074 shares Expires not disclosed F4 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 · derivative.exercise_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F5 · derivative.expiration_date: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 · derivative.underlying_shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 23,074 shares will be issued. If maximum performance metrics are achieved, 55,378 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 23:58 UTC |
KIIL HARRY SKIPEVP & President Cardiovascular
|
GrantOrdinary Shares | 9,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001708062-26-000010 · wk-form4_1785887900.xml · nonDerivative · entry 2 KIIL HARRY SKIP · CIK 0001708062 · EVP & President Cardiovascular 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,669 F3 · shares: Represents restricted stock units that vest 100% on the third anniversary of the date of grant. Read SEC document |
| July 31, 2026 Filed Aug 5, 2026 00:00 UTC |
Walter Matthew R.SVP, Chief HR Officer
|
Tax withholdingOrdinary Shares | 1,675 | $85.39 | $143,028.25 |
DisclosureSEC source: 0002028475-26-000010 · wk-form4_1785888007.xml · nonDerivative · entry 1 Walter Matthew R. · CIK 0002028475 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,159 F1 · shares: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 · balance_after: Includes 140 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 23:57 UTC |
Martha GeoffreyDirector · Chairman and CEO
|
Tax withholdingOrdinary Shares | 15,810 | $85.39 | $1,350,015.90 |
DisclosureSEC source: 0001560409-26-000008 · wk-form4_1785887872.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,333 F1 · shares: Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 · balance_after: Includes 980 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| July 31, 2026 Filed Aug 5, 2026 00:00 UTC |
Blomquist Denise L.Chief Accounting Officer
|
Tax withholdingOrdinary Shares | 212 | $85.39 | $18,102.68 |
DisclosureSEC source: 0002061393-26-000012 · wk-form4_1785888034.xml · nonDerivative · entry 1 Blomquist Denise L. · CIK 0002061393 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,661 F1 · shares: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 · balance_after: Includes 136 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 23:59 UTC |
Thompson KweliEVP & President, Neuroscience
|
Tax withholdingOrdinary Shares | 1,739 | $85.39 | $148,493.21 |
DisclosureSEC source: 0002137804-26-000004 · wk-form4_1785887983.xml · nonDerivative · entry 1 Thompson Kweli · CIK 0002137804 · EVP & President, Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,467 F1 · shares: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 · balance_after: Includes 188 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 23:58 UTC |
Marinaro MichaelEVP, Pres MedSurg and Americas
|
Tax withholdingOrdinary Shares | 3,356 | $85.39 | $286,568.84 |
DisclosureSEC source: 0001984186-26-000006 · wk-form4_1785887926.xml · nonDerivative · entry 1 Marinaro Michael · CIK 0001984186 · EVP, Pres MedSurg and Americas 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,313 F1 · shares: Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 · balance_after: Includes 547 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 23:58 UTC |
KIIL HARRY SKIPEVP & President Cardiovascular
|
Tax withholdingOrdinary Shares | 3,074 | $85.39 | $262,488.86 |
DisclosureSEC source: 0001708062-26-000010 · wk-form4_1785887900.xml · nonDerivative · entry 1 KIIL HARRY SKIP · CIK 0001708062 · EVP & President Cardiovascular 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,439 F1 · shares: Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 · balance_after: Includes 286 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| July 28, 2026 Filed Jul 29, 2026 21:00 UTC |
Quinn MichelleEVP, GC and Secretary
|
Tax withholdingOrdinary Shares | 2,069 | $86.88 | $179,754.72 |
DisclosureSEC source: 0001964281-26-000002 · wk-form4_1785358847.xml · nonDerivative · entry 1 Quinn Michelle · CIK 0001964281 · EVP, GC and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,375 F1 · shares: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 · balance_after: Includes 697 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| July 08, 2026 Filed Jul 9, 2026 20:26 UTC |
Walter Matthew R.SVP, Chief HR Officer
|
SaleOrdinary Shares | 3,102 | $83.15 | $257,931.30 |
DisclosureSEC source: 0002028475-26-000008 · wk-form4_1783628781.xml · nonDerivative · entry 1 Walter Matthew R. · CIK 0002028475 · SVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,694 F1 · balance_after: Includes 107 shares acquired under Medtronic's Employee Stock Ownership Plan since the last report filed by the reporting person. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 20:16 UTC |
KIIL HARRY SKIPEVP & President Cardiovascular
|
SaleOrdinary Shares | 228 | $80.45 | $18,342.60 |
DisclosureSEC source: 0001708062-26-000008 · wk-form4_1781036194.xml · nonDerivative · entry 2 KIIL HARRY SKIP · CIK 0001708062 · EVP & President Cardiovascular 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,227 Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 20:16 UTC |
KIIL HARRY SKIPEVP & President Cardiovascular
|
SaleOrdinary Shares | 3,961 | $80.44 | $318,622.84 |
DisclosureSEC source: 0001708062-26-000008 · wk-form4_1781036194.xml · nonDerivative · entry 1 KIIL HARRY SKIP · CIK 0001708062 · EVP & President Cardiovascular 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,455 Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 21:01 UTC |
Blomquist Denise L.Chief Accounting Officer
|
Tax withholdingOrdinary Shares | 237 | $83.32 | $19,746.84 |
DisclosureSEC source: 0002061393-26-000010 · wk-form4_1780952493.xml · nonDerivative · entry 1 Blomquist Denise L. · CIK 0002061393 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,737 F1 · shares: Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on April 24, 2026. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 21:02 UTC |
Walter Matthew R.SVP, Chief HR Officer
|
Tax withholdingOrdinary Shares | 2,840 | $83.32 | $236,628.80 |
DisclosureSEC source: 0002028475-26-000006 · wk-form4_1780952526.xml · nonDerivative · entry 1 Walter Matthew R. · CIK 0002028475 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,689 F1 · shares: Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on April 24, 2026. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 21:03 UTC |
Martha GeoffreyDirector · Chairman and CEO
|
Tax withholdingOrdinary Shares | 41,936 | $83.32 | $3,494,107.52 |
DisclosureSEC source: 0001560409-26-000006 · wk-form4_1780952594.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,163 F1 · shares: Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on April 24, 2026. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 21:07 UTC |
KIIL HARRY SKIPEVP & President Cardiovascular
|
Tax withholdingOrdinary Shares | 6,817 | $83.32 | $567,992.44 |
DisclosureSEC source: 0001708062-26-000006 · wk-form4_1780952847.xml · nonDerivative · entry 1 KIIL HARRY SKIP · CIK 0001708062 · EVP & President Cardiovascular 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,416 F1 · shares: Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on April 24, 2026. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 21:02 UTC |
Marinaro MichaelEVP, Pres MedSurg and Americas
|
Tax withholdingOrdinary Shares | 7,471 | $83.32 | $622,483.72 |
DisclosureSEC source: 0001984186-26-000004 · wk-form4_1780952558.xml · nonDerivative · entry 1 Marinaro Michael · CIK 0001984186 · EVP, Pres MedSurg and Americas 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,122 F1 · shares: Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on April 24, 2026. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:26 UTC |
Walter Matthew R.SVP, Chief HR Officer
|
Exercise / conversionPerformance Share Unit · Derivative | 8,449 | $0.00 | $0.00 |
DisclosureSEC source: 0002028475-26-000004 · wk-form4_1780000015.xml · derivative · entry 2 Walter Matthew R. · CIK 0002028475 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,449 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F3 · derivative.exercise_date: The performance share units vested on April 24, 2026. F3 · derivative.expiration_date: The performance share units vested on April 24, 2026. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:26 UTC |
Walter Matthew R.SVP, Chief HR Officer
|
Exercise / conversionOrdinary Shares | 9,149 | $0.00 | $0.00 |
DisclosureSEC source: 0002028475-26-000004 · wk-form4_1780000015.xml · nonDerivative · entry 1 Walter Matthew R. · CIK 0002028475 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares issued upon the settlement of performance-vesting share units granted on July 31, 2023, based on performance as certified on May 26, 2026. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:26 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
Exercise / conversionPerformance Share Unit · Derivative | 24,214 | $0.00 | $0.00 |
DisclosureSEC source: 0001473812-26-000002 · wk-form4_1779999981.xml · derivative · entry 2 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 24,214 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F4 · derivative.exercise_date: The performance share units vested on April 24, 2026. F4 · derivative.expiration_date: The performance share units vested on April 24, 2026. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:26 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
Exercise / conversionOrdinary Shares | 26,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001473812-26-000002 · wk-form4_1779999981.xml · nonDerivative · entry 1 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares issued upon the settlement of performance-vesting share units granted on July 31, 2023, based on performance as certified on May 26, 2026. F2 · balance_after: Includes 527 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:25 UTC |
Martha GeoffreyDirector · Chairman and CEO
|
Exercise / conversionPerformance Share Unit · Derivative | 85,461 | $0.00 | $0.00 |
DisclosureSEC source: 0001560409-26-000004 · wk-form4_1779999956.xml · derivative · entry 2 Martha Geoffrey · CIK 0001560409 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 85,461 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F4 · derivative.exercise_date: The performance share units vested on April 24, 2026. F4 · derivative.expiration_date: The performance share units vested on April 24, 2026. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:25 UTC |
Martha GeoffreyDirector · Chairman and CEO
|
Exercise / conversionOrdinary Shares | 94,963 | $0.00 | $0.00 |
DisclosureSEC source: 0001560409-26-000004 · wk-form4_1779999956.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares issued upon the settlement of performance-vesting share units granted on July 31, 2023, based on performance as certified on May 26, 2026. F2 · balance_after: Includes 1,743 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.